X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1452) 1452
diabetes mellitus, type 2 - drug therapy (1107) 1107
hypoglycemic agents - therapeutic use (857) 857
sodium-glucose transporter 2 - antagonists & inhibitors (709) 709
diabetes (686) 686
glucose (658) 658
male (622) 622
type 2 diabetes (604) 604
glucosides - therapeutic use (558) 558
endocrinology & metabolism (550) 550
female (486) 486
middle aged (434) 434
diabetes mellitus (432) 432
dapagliflozin (429) 429
animals (417) 417
double-blind (398) 398
benzhydryl compounds - therapeutic use (389) 389
sodium-glucose transporter 2 inhibitors - therapeutic use (382) 382
dextrose (358) 358
pharmacology & pharmacy (358) 358
hypoglycemic agents - adverse effects (342) 342
sodium (332) 332
treatment outcome (329) 329
canagliflozin (306) 306
insulin (303) 303
sodium-glucose transporter 2 - metabolism (303) 303
aged (295) 295
diabetes mellitus, type 2 - blood (291) 291
hypoglycemic agents - pharmacology (291) 291
empagliflozin (282) 282
diabetes mellitus, type 2 - complications (271) 271
blood glucose - metabolism (262) 262
blood glucose - drug effects (251) 251
metformin (251) 251
sglt2 inhibitor (248) 248
hyperglycemia (247) 247
type 2 diabetes mellitus (246) 246
safety (245) 245
risk factors (238) 238
glycemic control (231) 231
glucosides - adverse effects (229) 229
adult (224) 224
diabetes mellitus, type 2 - metabolism (223) 223
glucosides - pharmacology (206) 206
clinical trials (203) 203
blood pressure (202) 202
hypoglycemic agents (201) 201
sglt2 inhibitors (200) 200
type-2 diabetes-mellitus (199) 199
inadequate glycemic control (193) 193
analysis (190) 190
care and treatment (187) 187
mellitus (187) 187
hypoglycemic agents - administration & dosage (182) 182
internal medicine (179) 179
efficacy (178) 178
dipeptidyl-peptidase iv inhibitors - therapeutic use (170) 170
drug therapy, combination (170) 170
glucose - metabolism (168) 168
drug therapy (167) 167
heart failure (164) 164
abridged index medicus (155) 155
mortality (155) 155
benzhydryl compounds - adverse effects (154) 154
canagliflozin - therapeutic use (153) 153
cardiac & cardiovascular systems (153) 153
sodium-glucose transporter 2 inhibitors - adverse effects (153) 153
diabetes therapy (152) 152
body weight (151) 151
medicine, general & internal (151) 151
sodium-glucose transporter 2 inhibitors (145) 145
medicine & public health (144) 144
inhibitors (143) 143
cardiovascular diseases - prevention & control (141) 141
benzhydryl compounds - pharmacology (138) 138
glucose transporter (138) 138
diabetes mellitus, type 2 - physiopathology (137) 137
glycated hemoglobin a - metabolism (137) 137
risk (134) 134
blood-pressure (131) 131
metformin - therapeutic use (131) 131
insulin resistance (129) 129
double-blind method (128) 128
patients (128) 128
thiophenes - therapeutic use (126) 126
mice (125) 125
randomized controlled trials as topic (125) 125
research (125) 125
kidney - drug effects (123) 123
kidney - metabolism (121) 121
metabolism (119) 119
hypoglycemia (118) 118
blood pressure - drug effects (117) 117
cardiovascular disease (117) 117
review (117) 117
glucose metabolism (116) 116
rats (115) 115
cardiovascular diseases (113) 113
glucosides - administration & dosage (112) 112
sglt2 (110) 110
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1725) 1725
German (31) 31
Spanish (19) 19
French (13) 13
Japanese (11) 11
Czech (4) 4
Korean (4) 4
Danish (3) 3
Dutch (3) 3
Italian (2) 2
Portuguese (2) 2
Russian (2) 2
Swedish (2) 2
Chinese (1) 1
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European journal of heart failure, ISSN 1388-9842, 2017, Volume 19, Issue 11, pp. 1390 - 1400
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 11, p. e0166125
Objective Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes... 
ADD-ON THERAPY | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | LIVER-FUNCTION TESTS | SGLT2 INHIBITOR | MULTIDISCIPLINARY SCIENCES | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | METFORMIN PLUS SULFONYLUREA | JAPANESE PATIENTS | INADEQUATE GLYCEMIC CONTROL | LONG-TERM EFFICACY | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 - metabolism | Glycated Hemoglobin A - metabolism | Humans | Sodium-Glucose Transporter 2 Inhibitors | Treatment Outcome | Diabetes Mellitus, Type 2 - metabolism | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Canagliflozin - therapeutic use | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Type 2 diabetes | Medical research | Complications and side effects | Heart beat | Analysis | Glycosylated hemoglobin | Medicine, Experimental | Lipids | Glucose | Drug therapy | Dextrose | Diabetes therapy | Drugs | Genital tract | Pressure effects | Heart attacks | Liver | Bias | Body weight | Clinical trials | Cardiovascular disease | Systematic review | Infections | Cancer therapies | Blood | Confidence intervals | Quality | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Creatinine | Glucose transporter | Alanine | Peptidase | Liver diseases | Kidneys | Diabetes mellitus | Data processing | FDA approval | Hypoglycemia | Metabolism | Patients | Heart rate | Studies | Hospitals | Inhibitors | Sodium | Ketoacidosis | Alanine transaminase | Metformin | Diabetes | Clinical medicine | Transporter
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 6, pp. 1150 - 1166
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 23, pp. 2628 - 2639
BACKGROUND Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i... 
heart failure | SEVERE HYPOGLYCEMIA | SULFONYLUREA | death | INITIATION | SGLT-2 inhibitor | diabetes mellitus | sodium glucose cotransporter-2 inhibitors | ALL-CAUSE MORTALITY | ORGANIZATION | JAPANESE HOSPITAL DATABASE | ASIA | LOWER RISK | DPP-4 INHIBITORS | observational studies | CARDIAC & CARDIOVASCULAR SYSTEMS | INSULIN | OUTCOMES | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Male | Diabetes Mellitus, Type 2 - epidemiology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Internationality | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Electronic Health Records | Cohort Studies | Glucose | Chemical vapor deposition | Analysis | Dextrose | Heart | Drugs | Laboratories | Identification methods | Personal health | Clinical trials | Medical records | Subgroups | Matching | Confidence intervals | Databases | Risk assessment | Diuretics | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Health insurance | Stroke | Payment systems | Diabetes mellitus | Mortality | Health risks | Patients | Prescription drugs | Hospitals | Inhibitors | Sodium | Death | Diabetes | Clinical medicine | Cardiovascular diseases | Pharmaceuticals
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher or lower rate of cardiovascular death... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Life Sciences | Food and Nutrition | Animal biology | Cellular Biology | Pharmaceutical sciences | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article